clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- J. Antimicrob. Chemother. (1)
- Clin. Diagn. Lab. Immunol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Svensson M et al. | Pharmacodynamic effects of nitroimidazoles alone and in combination with clarithromycin on Helicobacter pylori. | 2002 | Antimicrob. Agents Chemother. | pmid:12069981 |
| Gibreel A et al. | Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni. | 2007 | Antimicrob. Agents Chemother. | pmid:17606685 |
| Comley JC and Sterling AM | Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. | 1995 | Antimicrob. Agents Chemother. | pmid:7785975 |
| Struillou L et al. | Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. | 1995 | Antimicrob. Agents Chemother. | pmid:7785988 |
| Endo H et al. | Effects of lansoprazole and amoxicillin on uptake of [(14)C]clarithromycin into gastric tissue in rats. | 2001 | Antimicrob. Agents Chemother. | pmid:11709323 |
| Goswami S et al. | Anti-Helicobacter pylori potential of artemisinin and its derivatives. | 2012 | Antimicrob. Agents Chemother. | pmid:22687518 |
| Taylor DE et al. | Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. | 1997 | Antimicrob. Agents Chemother. | pmid:9420030 |
| Nash KA and Inderlied CB | Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. | 1995 | Antimicrob. Agents Chemother. | pmid:8592991 |
| Alder J et al. | Clarithromycin therapy of experimental Treponema pallidum infections in hamsters. | 1993 | Antimicrob. Agents Chemother. | pmid:8494384 |
| Cho SH et al. | Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. | 2007 | Antimicrob. Agents Chemother. | pmid:17210775 |
| Ji B et al. | Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. | 2007 | Antimicrob. Agents Chemother. | pmid:17664316 |
| Yasuda H et al. | Interaction between clarithromycin and biofilms formed by Staphylococcus epidermidis. | 1994 | Antimicrob. Agents Chemother. | pmid:8141568 |
| Vaara M | Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. | 1993 | Antimicrob. Agents Chemother. | pmid:8383945 |
| Fujii K et al. | In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. | 1994 | Antimicrob. Agents Chemother. | pmid:8067748 |
| Bakker-Woudenberg IA et al. | Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination. | 2005 | Antimicrob. Agents Chemother. | pmid:15917538 |
| Traunmüller F et al. | Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. | 2007 | Antimicrob. Agents Chemother. | pmid:17606673 |
| Kim YC et al. | Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus. | 2005 | Antimicrob. Agents Chemother. | pmid:15917564 |
| Romand S et al. | In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. | 1993 | Antimicrob. Agents Chemother. | pmid:8285620 |
| Yasuda H et al. | Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8239580 |
| Kalach N et al. | Clarithromycin resistance and eradication of Helicobacter pylori in children. | 2001 | Antimicrob. Agents Chemother. | pmid:11408237 |
| Alder J et al. | Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo. | 1993 | Antimicrob. Agents Chemother. | pmid:8328782 |
| Mor N and Heifets L | Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8328792 |
| Rastogi N et al. | Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. | 1991 | Antimicrob. Agents Chemother. | pmid:1667250 |
| Koh WJ et al. | Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. | 2015 | Antimicrob. Agents Chemother. | pmid:25987622 |
| Hultén K et al. | New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. | 1996 | Antimicrob. Agents Chemother. | pmid:9124830 |
| Cynamon MH and Klemens SP | Activity of azithromycin against Mycobacterium avium infection in beige mice. | 1992 | Antimicrob. Agents Chemother. | pmid:1329622 |
| Bermudez LE et al. | Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. | 1994 | Antimicrob. Agents Chemother. | pmid:7986018 |
| Khan AA et al. | Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis. | 1997 | Antimicrob. Agents Chemother. | pmid:9145840 |
| Collins L and Franzblau SG | Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. | 1997 | Antimicrob. Agents Chemother. | pmid:9145860 |
| Lounis N et al. | Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. | 1997 | Antimicrob. Agents Chemother. | pmid:9145892 |
| Osborne CS et al. | In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. | 2009 | Antimicrob. Agents Chemother. | pmid:19596876 |
| Cavalieri SJ et al. | Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. | 1995 | Antimicrob. Agents Chemother. | pmid:7492101 |
| Bosnar M et al. | Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. | 2005 | Antimicrob. Agents Chemother. | pmid:15917536 |
| Subramanian S et al. | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. | 2008 | Antimicrob. Agents Chemother. | pmid:18070962 |
| Moon JE et al. | Efficacy of macrolides and telithromycin against leptospirosis in a hamster model. | 2006 | Antimicrob. Agents Chemother. | pmid:16723556 |
| Burton AJ et al. | Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice. | 2015 | Antimicrob. Agents Chemother. | pmid:25824218 |
| Leuthner KD et al. | Pulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniae. | 2006 | Antimicrob. Agents Chemother. | pmid:16436754 |
| Kohyama T et al. | Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. | 1999 | Antimicrob. Agents Chemother. | pmid:10103198 |
| Walzer PD et al. | Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies. | 1997 | Antimicrob. Agents Chemother. | pmid:9021174 |
| Banerjee DK et al. | Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy. | 1997 | Antimicrob. Agents Chemother. | pmid:9021187 |
| Schuster S et al. | Evidence of a Substrate-Discriminating Entrance Channel in the Lower Porter Domain of the Multidrug Resistance Efflux Pump AcrB. | 2016 | Antimicrob. Agents Chemother. | pmid:27161641 |
| Cirioni O et al. | Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. | 2008 | Antimicrob. Agents Chemother. | pmid:18779356 |
| Lonks JR and Medeiros AA | High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I. | 1993 | Antimicrob. Agents Chemother. | pmid:8239578 |
| Klopman G et al. | Anti-Mycobacterium avium activity of quinolones: in vitro activities. | 1993 | Antimicrob. Agents Chemother. | pmid:8239587 |
| Abduljalil K et al. | Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. | 2009 | Antimicrob. Agents Chemother. | pmid:19414584 |
| Hoppe JE and Bryskier A | In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). | 1998 | Antimicrob. Agents Chemother. | pmid:9559823 |
| Dever LL et al. | Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. | 1993 | Antimicrob. Agents Chemother. | pmid:8215288 |
| Kashuba AD and Amsden GW | Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9527816 |
| Clark CL et al. | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. | 2007 | Antimicrob. Agents Chemother. | pmid:17876003 |
| Amsden GW et al. | Oral cimetidine prolongs clarithromycin absorption. | 1998 | Antimicrob. Agents Chemother. | pmid:9660986 |
| Liou JM et al. | Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. | 2011 | Antimicrob. Agents Chemother. | pmid:21189342 |
| Kosowska K et al. | Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. | 2004 | Antimicrob. Agents Chemother. | pmid:15504829 |
| Bae S et al. | Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance. | 2010 | Antimicrob. Agents Chemother. | pmid:19884366 |
| Klemens SP and Cynamon MH | Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice. | 1994 | Antimicrob. Agents Chemother. | pmid:7986001 |
| Spyridaki A et al. | Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. | 2012 | Antimicrob. Agents Chemother. | pmid:22564837 |
| Stone GG et al. | A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. | 1997 | Antimicrob. Agents Chemother. | pmid:9056021 |
| Furuie H et al. | Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. | 2010 | Antimicrob. Agents Chemother. | pmid:19933801 |
| Tessier PR et al. | Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. | 2002 | Antimicrob. Agents Chemother. | pmid:11959578 |
| Ichiyama T et al. | Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. | 2001 | Antimicrob. Agents Chemother. | pmid:11120942 |
| Bohnert JA et al. | Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay. | 2016 | Antimicrob. Agents Chemother. | pmid:26824939 |
| Ji B et al. | Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. | 1991 | Antimicrob. Agents Chemother. | pmid:1828136 |
| Heifets L et al. | Mycobacterium avium strains resistant to clarithromycin and azithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8031351 |
| Miltner EC and Bermudez LE | Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. | 2000 | Antimicrob. Agents Chemother. | pmid:10858369 |
| Kawai Y et al. | Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. | 2013 | Antimicrob. Agents Chemother. | pmid:23459497 |
| Nakamura S et al. | Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. | 2010 | Antimicrob. Agents Chemother. | pmid:19949056 |
| Bermudez LE et al. | Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice. | 2012 | Antimicrob. Agents Chemother. | pmid:22615290 |
| Jorgensen JH et al. | Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. | 1991 | Antimicrob. Agents Chemother. | pmid:1834012 |
| Cynamon MH et al. | Comparative activities of azithromycin and clarithromycin against Mycobacterium avium infection in beige mice. | 1994 | Antimicrob. Agents Chemother. | pmid:7979270 |
| Greendyke R and Byrd TF | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. | 2008 | Antimicrob. Agents Chemother. | pmid:18378709 |
| Fernandez-Martin J et al. | Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. | 1991 | Antimicrob. Agents Chemother. | pmid:1836943 |
| Jesus FP et al. | In Vitro and In Vivo Antimicrobial Activities of Minocycline in Combination with Azithromycin, Clarithromycin, or Tigecycline against Pythium insidiosum. | 2015 | Antimicrob. Agents Chemother. | pmid:26459895 |
| Ferro BE et al. | Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. | 2016 | Antimicrob. Agents Chemother. | pmid:26643335 |
| Andini N and Nash KA | Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. | 2006 | Antimicrob. Agents Chemother. | pmid:16801446 |
| Goldstein EJ et al. | Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. | 1998 | Antimicrob. Agents Chemother. | pmid:9593139 |
| van Doorn LJ et al. | Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. | 2001 | Antimicrob. Agents Chemother. | pmid:11302817 |
| Rastogi N et al. | In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4. | 2000 | Antimicrob. Agents Chemother. | pmid:10991870 |
| Piccolomini R et al. | In vitro activity of clarithromycin against intracellular Helicobacter pylori. | 2001 | Antimicrob. Agents Chemother. | pmid:11302831 |
| Fernandes PB et al. | In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. | 1986 | Antimicrob. Agents Chemother. | pmid:2949695 |
| Segreti J et al. | In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. | 1987 | Antimicrob. Agents Chemother. | pmid:2952061 |
| Benson CA et al. | In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. | 1987 | Antimicrob. Agents Chemother. | pmid:2952063 |
| Gelber RH et al. | Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. | 1991 | Antimicrob. Agents Chemother. | pmid:1648889 |
| Barry AL et al. | In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. | 1987 | Antimicrob. Agents Chemother. | pmid:2952064 |
| Chin NX et al. | Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. | 1987 | Antimicrob. Agents Chemother. | pmid:2953303 |
| Brophy DF et al. | Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. | 2000 | Antimicrob. Agents Chemother. | pmid:10722500 |
| Matsuzaki J et al. | Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. | 2012 | Antimicrob. Agents Chemother. | pmid:22203601 |
| Bowie WR et al. | In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. | 1987 | Antimicrob. Agents Chemother. | pmid:2953304 |
| Derouin F et al. | Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis. | 1992 | Antimicrob. Agents Chemother. | pmid:1482160 |
| Goldstein EJ and Citron DM | Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents. | 1993 | Antimicrob. Agents Chemother. | pmid:8390810 |
| Giamarellos-Bourboulis EJ et al. | Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. | 2004 | Antimicrob. Agents Chemother. | pmid:14693524 |
| Hultén K et al. | Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. | 1997 | Antimicrob. Agents Chemother. | pmid:9371366 |
| Carter G et al. | A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. | 2004 | Antimicrob. Agents Chemother. | pmid:15561879 |
| Yamazaki T et al. | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. | 2007 | Antimicrob. Agents Chemother. | pmid:17387152 |
| Walker KJ et al. | Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model. | 1994 | Antimicrob. Agents Chemother. | pmid:7811010 |
| Bogdanovich T et al. | Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae. | 2006 | Antimicrob. Agents Chemother. | pmid:16495248 |
| Welsh L et al. | In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. | 1996 | Antimicrob. Agents Chemother. | pmid:8787907 |
| Garey KW et al. | Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. | 1999 | Antimicrob. Agents Chemother. | pmid:10223928 |
| Nagaoka K et al. | Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells. | 2013 | Antimicrob. Agents Chemother. | pmid:23380724 |
| Renvoisé A et al. | Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex. | 2015 | Antimicrob. Agents Chemother. | pmid:26324275 |
| Nash KA | Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38). | 2003 | Antimicrob. Agents Chemother. | pmid:14506008 |
| Best LM et al. | Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. | 2003 | Antimicrob. Agents Chemother. | pmid:14506021 |